Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$7.47M+3.4%$9.77M+17.3%$6.31M-36.4%$8.1M-37.1%$7.22M-49.0%
$104.65M+71.8%$86.4M+30.9%$76.78M+21.2%$65.98M+9.6%$60.91M-6.2%
$35.39M+17.9%$33.87M+17.0%$31.66M+9.0%$31.29M+5.2%$30.03M+5.8%
$140.03M+46.2%$120.27M+20.5%$108.44M+11.0%$102.1M+12.2%$95.77M+1.5%
$140.03M+46.2%$120.27M+20.5%$108.44M+11.0%$102.1M+12.2%$95.77M+1.5%
-$132.56M-49.7%-$110.5M-20.8%-$102.13M-16.4%-$94M-20.3%-$88.55M-10.4%
-1,774.4%-549pp-1,130.6%-33.1pp-1,618.5%-733pp-1,160.8%-554pp-1,225.8%-659pp
$53K-42.4%$63K-38.2%$73K-90.8%$82K-96.3%$92K-97.5%
$10.48M+59.5%$9.22M+32.9%$8.05M+12.5%$6.99M+13.5%$6.57M
$2.69M+50.6%$1.5M-30.4%$2.2M$1.28M$1.78M
-$129.88M-49.7%-$109M-22.1%-$99.93M-$92.72M-$86.77M
-1,738.4%-537pp-1,115.3%-43.6pp-1,583.7%-1,145%-1,201.1%
-$0.38-11.8%-$0.34+5.6%-$0.33-$0.34-$0.34
-$0.38-11.8%-$0.34+5.6%-$0.33-$0.34-$0.34
1.3B+31.1%1.2B+26.3%1.2B+38.1%1.1B+53.7%1B+89.8%
1.3B+31.1%1.2B+26.3%1.2B+38.1%1.1B+53.7%1B+89.8%
$6.11M+20.7%$6.17M+34.6%$5.07M+14.8%$5.24M+69.0%$5.06M+129%
$1.3M+386%$1.2M+7,594%$380K$13K-$455K
-$335K-264%-$291K-165%-$327K-388%-$371K-7,320%-$92K-109%
-$132.56M-49.7%-$110.5M-20.8%-$102.13M-16.4%-$94M-20.3%-$88.55M-10.4%
-$131.47M-50.5%-$109.42M-21.3%-$101.04M-16.8%-$92.82M-20.8%-$87.36M-10.8%
-$131.47M-50.5%-$109.42M-21.3%-$101.04M-16.8%-$92.82M-20.8%-$87.36M-10.8%
-1,759.7%-550pp-1,119.6%-36.8pp-1,601.3%-729pp-1,146.2%-549pp-1,209.3%-653pp
-$132.56M-49.7%-$110.5M-20.8%-$102.13M-16.4%-$94M-20.3%-$88.55M-10.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Taysha Gene Therapies, Inc.'s income statement data come from?
Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.